Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney

Preventing major adverse cardiovascular events by SGLT-2 inhibition in patients with type 2 diabetes: the role of kidney

Abstract Cardiovascular outcome trials (CVOTs) have demonstrated a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) treated by SGLT-2 inhibitors. This holds true in the presence of background therapy with statins in most patients. Noteworthy,...

Full description

Bibliographic Details
Main Authors: Dario Giugliano, Luca De Nicola, Maria Ida Maiorino, Giuseppe Bellastella, Carlo Garofalo, Paolo Chiodini, Antonio Ceriello, Katherine Esposito
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Cardiovascular Diabetology
Subjects:
SGLT-2 inhibitors
Type 2 diabetes
MACE
Diabetic kidney disease
Statin therapy
Online Access:http://link.springer.com/article/10.1186/s12933-020-01010-x

Internet

http://link.springer.com/article/10.1186/s12933-020-01010-x

Similar Items